Federated Hermes
NVCT icon

Federated Hermes’s Nuvectis Pharma NVCT Stock Holding History

Federated Hermes’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$920 Buy
+50
New +$560 ﹤0.01% 2014

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Federated Hermes's NVCT Position: Q2 2026 in Review

Federated Hermes opened a new position in Nuvectis Pharma (NVCT) in Q2 2026: 50 shares worth $920. The stake represents ﹤0.01% of the portfolio and ranks #2014 among its holdings.

83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Federated Hermes held 50 shares of Nuvectis Pharma worth $920 as of Q2 2026.
  • Nuvectis Pharma was a new Federated Hermes position in Q2 2026.
  • Nuvectis Pharma made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #2014 holding.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.